Education
About Us
Working with TipRanks
Follow Us
Michael Cochrane Insider Profile
4 Followers
Michael Cochrane, Director at Cytophage Technologies Ltd., holds 225.00K shares in Cytophage Technologies Ltd. (Ticker: TSE:CYTO). Most recently, Michael Cochrane Bought 75,000 shares of Cytophage Technologies Ltd. on Aug 21, 2025 for an estimated value of C$15.00K.
Michael Cochrane has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Michael Cochrane's holdings
Insider Roles
Director
Roles that Michael Cochrane holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Aug 21, 2025 - Today
Return:-4.00%
The most profitable trade made by Michael Cochrane
Michael Cochrane's Trading History
List of latest transactions for each holding click on a transaction to see Michael Cochrane's performance on stock
You May Also Like
Michael Cochrane insider profile FAQ
What is the percentage of profitable transactions made by Michael Cochrane?
The percentage of profitable transactions made by Michael Cochrane is ―.
What is the average return per transaction made by Michael Cochrane?
The average return per transaction made by Michael Cochrane is ―.
What stocks does Michael Cochrane hold?
Michael Cochrane holds: TSE:CYTO stocks.
What was Michael Cochrane’s latest transaction?
Michael Cochrane latest transaction was an Informative Buy of C$15.00K.
What was Michael Cochrane's most profitable transaction?
Michael Cochrane’s most profitable transaction was an Informative Buy of TSE:CYTO stock on August 21, 2025. The return on the trade was -4.00%.
What is Michael Cochrane's role in Cytophage Technologies Ltd.?
Michael Cochrane's role in Cytophage Technologies Ltd. is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.